Paula Ragan - X4 Pharmaceuticals President CEO, Secretary, Director
| XFOR Stock | USD 4.33 -0.33 -7.08% |
CEO
Dr. Paula Ragan, Ph.D. is President, Chief Executive Officer, Secretary, Director of the Company. She was X4s President and Chief Executive Officer and a member of the X4 board of directors since July 2014. She has more than 18 years of experience building companies in the biotechnology industry. From August 2012 to September 2014, Dr. Ragan consulted as Chief Business Officer at Lysosomal Therapeutics Inc., a private biopharmaceutical company, where she led the companys business development activities. Prior to that, from January 2007 to August 2012, Dr. Ragan held leadership roles in corporate development and operations at Genzyme Corporation, a Sanofi company, where she led strategic partnering efforts for Genzymes Rare Disease business and headed the supply chain planning for Genzymes flagship commercial products. Other professional roles include business roles at Hydra Biosciences, Oscient Corporation and Celera Corporation since 2019.
| Age | 55 |
| Tenure | 7 years |
| Professional Marks | Ph.D |
| Address | 61 North Beacon Street, Boston, MA, United States, 02134 |
| Phone | 857 529 8300 |
| Web | https://www.x4pharma.com |
Paula Ragan Latest Insider Activity
Insider activity for Paula Ragan can add context to X4 Pharmaceuticals by showing net buying or selling trends across reporting periods. Use filings as supporting evidence, not a standalone signal, because transaction motives can differ.
Paula Ragan over three months ago Disposition of 49678 shares by Paula Ragan of X4 Pharmaceuticals at 0.8828 subject to Rule 16b-3 | ||
Paula Ragan over a year ago Acquisition by Paula Ragan of 169940 shares of X4 Pharmaceuticals subject to Rule 16b-3 | ||
Paula Ragan over a year ago Disposition of 31897 shares by Paula Ragan of X4 Pharmaceuticals at 0.562 subject to Rule 16b-3 | ||
Paula Ragan over a year ago Disposition of 6724 shares by Paula Ragan of X4 Pharmaceuticals at 2.23 subject to Rule 16b-3 |
X4 Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of -33.54 % which suggests that the asset base is not productive at current operating levels. This is extremely low compared to the sector. Similarly, it shows a return on stockholder's equity (ROE) of -156.87 %, which implies that returns to shareholders were negative during the period.Similar Executives
| Found 2 records | CEO Age | ||
| Lawrence Chen | InterDigital | 53 | |
| Lawrence JD | InterDigital | 55 | |
Management Performance
| Return On Equity | -1.57 | ||||
| Return On Asset | -0.34 |
X4 Pharmaceuticals Leadership Team
Elected by the shareholders, the X4 Pharmaceuticals' board of directors comprises two types of representatives: X4 Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of XFOR. The board's role is to monitor X4 Pharmaceuticals' management team and ensure that shareholders' interests are well served. X4 Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, X4 Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Brian Bowersox, VP Controller | ||
| Paula Ragan, President CEO, Secretary, Director | ||
| Adam Mostafa, CFO, Treasurer, Assistant Secretary | ||
| Renato Skerlj, Founder | ||
| Arthur Taveras, Chief Officer | ||
| Murray MD, Interim Director | ||
| Mark MBA, Chief Officer | ||
| Richard MD, Chairman Founder | ||
| MBA MD, Chief Officer | ||
| Natasha Esq, Chief Officer | ||
| Robert Arbeit, Senior Research | ||
| Mary DiBiase, Chief Officer | ||
| Keith MD, Founder Board | ||
| Pharm MPH, Vice Communications | ||
| John Volpone, President COO | ||
| David Kirske, Chief Officer |
XFOR Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is X4 Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.57 | ||||
| Return On Asset | -0.34 | ||||
| Profit Margin | -2.80 % | ||||
| Operating Margin | -12.81 % | ||||
| Current Valuation | 363.06 M | ||||
| Shares Outstanding | 87.44 M | ||||
| Shares Owned By Insiders | 1.15 % | ||||
| Shares Owned By Institutions | 93.88 % | ||||
| Number Of Shares Shorted | 3.38 M | ||||
| Price To Book | 6.62 X |
Pair Trading with X4 Pharmaceuticals
Pair trading with X4 Pharmaceuticals can help investors hedge some company-specific exposure by balancing a long view with an offsetting position. The key question is whether the second leg adds real hedge value instead of just creating a more complex version of the same risk.
Moving against XFOR Stock
| 0.52 | GILD | Gilead Sciences | PairCorr |
| 0.44 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.36 | KPTI | Karyopharm Therapeutics | PairCorr |
Sophisticated investors use correlation analysis to build X4 Pharmaceuticals replacement strategies that go beyond simple sector matching. Assets with similar factor exposures to X4 Pharmaceuticals provide the most accurate portfolio substitution during tax-loss harvesting periods.
Statistical correlation between X4 Pharmaceuticals and its peers is an essential input for mean-variance portfolio optimization. Lower correlation of X4 Pharmaceuticals with other holdings allows for a more efficient frontier with superior risk-adjusted returns.
Correlation analysis and pair evaluation for X4 Pharmaceuticals can support hedging context. This approach is commonly reviewed within sectors and across broader groups.Additional Tools for XFOR Stock Analysis
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |